(S034) Pilot Phase II Trial of “Sandwich” Radiation and Combination Carboplatin and Paclitaxel Chemotherapy in Patients With High-Risk Endometrial Cancer

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Sandwich chemotherapy and radiation therapy is a tolerable treatment modality for patients with high-risk endometrial cancer. Rates of hematologic toxicities are acceptable, and nonhematologic toxicities are uncommon. Further enrollment of patients is underway to determine efficacy.

Lori Spoozak, MD, MHS, Divya Gupta, MD, Laura Reimers, MPH, Jennifer Jorgensen, MD, Rafi Kabarriti, MD, Keyur Mehta, MD, Gary Goldberg, MD, Mark Einstein, MD, MS, Dennis Yi-Shin Kuo, MD; Albert Einstein College of Medicine; Weill Cornell Medical College

OBJECTIVES: We sought to determine the toxicity, tolerability, and outcome of radiation therapy (RT) sandwiched between combination chemotherapy in patients (pts) with high-risk endometrial cancer.

METHODS: High-risk endometrial cancer was defined as surgically staged endometrioid adenocarcinoma, IA with grade (G) 3 tumor and with lymphovascular space involvement, IB with G2 or 3 tumor, and stage II–IV disease, any grade. Treatment involved paclitaxel (T) (175 mg/m2) and carboplatin (C) (area under the concentration-time curve [AUC] = 6.0 or 6.5) every 21 days × 3 doses, followed by pelvic external beam radiation therapy (45 Gy) and brachytherapy (15 Gy). Per protocol, brachytherapy only (25 Gy) was administered to pts with stage IA G3 and IB G2 disease. Three additional cycles of T/C (AUC = 5) were administered after RT. Toxicity was graded by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Analysis of toxicities was performed on all evaluable pts.

RESULTS: A total of 21 pts were enrolled between 2008–2014. The median age was 62 years (range: 48–74 yr): 66.7% (14/21) pts had stage I/II disease, while the remaining 33.3% (7/21) had stage IIIC disease; 42.9% (9/21) had International Federation of Gynecology and Obstetrics (FIGO) G1 disease, and 23.8% (5/21) and 33.3% (7/21) had G2 and 3 disease, respectively; 66.7% (14/21) pts completed the treatment per protocol; and 76.2% (16/21) pts completed six cycles of chemotherapy. One pt refused chemotherapy after enrollment, and four pts could not complete chemotherapy due to hematologic toxicities. Of 115 evaluable chemotherapy cycles, the G3 or 4 combined hematologic toxicity events were as follows: 33/115 cycles (28.7%) neutropenia, 9/115 cycles (7.8%) thrombocytopenia, and 10/115 cycles (8.7%) anemia. Of 105 evaluable chemotherapy cycles, the G3 or 4 combined nonhematologic events were as follows: 2/105 cycles (1.9%) infection, 1/105 cycles (0.95%) neuropathy, 4/105 (3.8%) metabolic, and 1/105 (0.95%) venous thromboembolism. Dose reduction occurred in 6/115 cycles (5.2%), and dose delay occurred in 12/115 cycles (10.4%). Since the study onset, 1 of 21 pts had a recurrence (lung) and died of disease.

CONCLUSIONS: Sandwich chemotherapy and radiation therapy is a tolerable treatment modality for patients with high-risk endometrial cancer. Rates of hematologic toxicities are acceptable, and nonhematologic toxicities are uncommon. Further enrollment of patients is underway to determine efficacy.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content